Frontiers Skin immune microenvironment in psoriasis: from bench to bedside Many treatment guidelines for psoriasis rely heavily on body surface area (BSA) involvement to determine disease severity and eligibility for systemic therapies like biologics. Traditionally, patients with less than 10% BSA involvementespecially Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non lesional and lesional skin Annals of the Rheumatic Diseases Targeted Oral Peptide Icotrokinra for Psoriasis Involving High Impact Sites NEJM Evidence Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week JACC